PubMedCrossRef 41 Petticrew M, Fraser J, Regan MF: Adverse life

PubMedCrossRef 41. Petticrew M, Fraser J, Regan MF: GSK1120212 in vivo Adverse life events and risk of breast cancer: a meta-analysis. Br J Health Psychol 1999, 4:1–17.CrossRef 42. Duijts SFA, Zeegers MP, Borne BV: The association between stressful life events and breast cancer risk: a meta-analysis. Int J Cancer 2003, 107:1023–1029.PubMedCrossRef 43. Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F: Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003,89(7):1221–1227.PubMedCrossRef 44. Vajdic CM, van Leeuwen MT: Cancer incidence and risk factors

after solid organ transplantation. Int J Cancer 2009,125(8):1747–1754.PubMedCrossRef Capmatinib chemical structure 45. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman

XMU-MP-1 cost JR, Webster AC, Kaldor JM, Grulich AE: Cancer incidence before and after kidney transplantation. JAMA 2006,296(23):2823–2931.PubMedCrossRef 46. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G: Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006, 332:385–393.PubMedCrossRef 47. Nomura K, Nakao M, Morimoto T: Effect of smoking on hearing loss: quality assessment and metaanalysis. Prev Med 2005, 40:138–144.PubMedCrossRef 48. Brouwers MC, Johnston ME, Charette ML, Hanna SE, Jadad AR, Browman GP: Evaluating the role of quality

assessment of primary studies in systematic reviews of cancer practice guidelines. BMC Med Res Methodol 2005, 5:8.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions YL and CW contributed equally to this work. Both designed the study, collected and analyzed data, and wrote the manuscript. YZ, XH, and LP participated in the collecting and analyzing data. GS and KW performed statistical analyses. QS conceived the study, participated in its design, and helped to draft the manuscript. All authors read and approved the final manuscript.”
“Background Epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 4-Aminobutyrate aminotransferase 19 and point mutations in exon 21, are considered the most reliable predictive factors of outcome after treatment of non-small cell lung cancer (NSCLC) with EGFR tyrosine kinase inhibitors (EGFR-TKIs). Gefitinib was approved as a first-line therapy for NSCLC based on the results of a phase III landmark study, the Iressa Pan-Asia Study (IPASS), which showed that gefitinib conferred a survival benefit in EGFR mutation-positive patients over conventional chemotherapy [1]. The trial clearly showed that the selection of EGFR-TKIs should be based on molecular markers, not on clinical characteristics.

Comments are closed.